What the research found

Since January 2026, six people in Victoria, Australia have developed acute liver failure after injecting products labelled as retatrutide purchased through unregulated channels. All six showed a consistent clinical pattern: elevated liver enzymes (ALT and AST) indicating hepatocyte damage, rising bilirubin suggesting impaired liver clearance function, and coagulopathy (reduced clotting ability) — the triad characteristic of acute liver failure. One 32-year-old required near-transplant level intervention after just two doses.

The state health alert identifies contamination as the likely culprit but stopped short of naming the specific contaminant at the time of publication, noting that laboratory analysis was ongoing. The vials were sold under multiple street names ("Retatrutide," "Reta," "R-10," "R-20") despite identical contents, suggesting common sourcing from unnamed manufacturers. Historical testing of gray-market semaglutide products has identified bacterial endotoxin (lipopolysaccharide) in every analysed sample — a known driver of inflammatory liver injury in animal models — though this remains one plausible explanation rather than confirmed cause in these cases.

Why it matters for you

If you're sourcing peptides outside regulated supply chains, this cluster demonstrates a concrete hepatotoxic risk. Even if you're receiving peptides from a practitioner, the supply chain opacity means contamination is possible at manufacture or repackaging. MyKine users tracking liver biomarkers (ALT, AST, bilirubin, GGT) should establish a baseline and monitor regularly if using off-market peptides — acute rises warrant immediate medical attention, not home management.

The speed of onset here is notable: severe liver injury within days of dosing. This isn't a slow accumulation you might catch through quarterly blood work. If you're self-administering any peptide, you should know the warning signs of acute hepatotoxicity: yellowing of skin or eyes, unexplained bruising, dark urine, severe nausea, or abdominal swelling. These require emergency evaluation, not protocol adjustment.

The rebranding across multiple names also signals that you have no way to verify consistency between batches, even from the same claimed source. Each vial is a separate risk assessment.

Caveats

• Investigation incomplete: The contaminant(s) causing liver injury had not been chemically identified at the time of the alert; mechanism remains presumed rather than confirmed
• Small case count: Six cases in one state; similar cases may exist in other Australian jurisdictions but numbers are unknown
• No product testing reported: The actual contents of the implicated vials had not been publicly released; contamination type is inferred from prior gray-market peptide testing, not direct analysis of these products
• Regulatory context: Retatrutide itself has never been approved anywhere, so all sourced versions are by definition unregulated; this is not a problem of counterfeit approved drug but absence of any legitimate supply chain